Biocryst Pharmaceuticals (BCRX) Current Deferred Revenue (2010 - 2026)

Biocryst Pharmaceuticals has reported Current Deferred Revenue for 15 years, with the latest figure at $5.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue changed N/A year-over-year to $5.4 million; the trailing twelve-month figure through Mar 2026 stood at $5.4 million (changed N/A YoY), and the FY2022 full-year result was $1.2 million, down 13.86% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $5.4 million, up from $522000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $5.4 million in Q1 2026, with the low at $522000.0 in Q3 2023.
• Historically, Current Deferred Revenue has averaged $1.8 million across 3 years, with a median of $1.5 million in 2022.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 263.21% — and 2023, when it plunged 66.41%.
• Biocryst Pharmaceuticals' Current Deferred Revenue stood at $1.2 million in 2022, then slumped by 57.35% to $522000.0 in 2023, then soared by 936.21% to $5.4 million in 2026.
• The last three Current Deferred Revenue figures came in at $5.4 million (Q1 2026), $522000.0 (Q3 2023), and $1.8 million (Q2 2023), per Business Quant data.